DIAGNOS Secures Saudi FDA Nod for AI Retinal Imaging System…

Event summary

DIAGNOS received Saudi FDA medical device license for CARA System on August 13, 2026.
CARA detects Diabetic Retinopathy and Age-related Macular Degeneration in retinal images.
Saudi Arabia has 5M+ adults with diabetes needing regular screening per International Diabetes Federation data.
DIAGNOS partners with local distributor Kanhoor Medical for market entry.

The big picture

This approval marks DIAGNOS' first major regulatory win outside North America, following Health Canada's clearance last month. The move positions the company to tap into a substantial diabetic retinopathy screening market while demonstrating the global scalability of its AI-powered diagnostic platform. Success in Saudi Arabia could serve as a blueprint for expansion into other high-prevalence diabetes regions.

What we're watching

Market Penetration: How effectively DIAGNOS can leverage Kanhoor Medical's distribution network to capture the Saudi market.
Regulatory Momentum: Whether this approval accelerates similar authorizations in other Middle Eastern markets.
Competitive Positioning: The pace at which DIAGNOS can differentiate CARA from existing retinal imaging solutions in the region.